Financial & competing interests disclosure
Marco Mula has received travel grants or consultancy fees from various pharmaceutical companies including Novartis, Pfizer, UCB Pharma, Eisai, Janssen-Cilag and Sanofi-Aventis. Josemir W Sander has received travel grants or consultancy fees from various pharmaceutical companies including UCB Pharma, Eisai, Janssen-Cilag,and GSK – involved in the manufacture of antiepileptic drugs. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.